During the past decade, Kagawa Prefectural Central Hospital conducted 40 clinical trials. In the 10-year time frame, 40 clinical trials started and 13 clinical trials were completed, i.e. on average, 32.5% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 11 clinical trials were completed. i.e. 52.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kagawa Prefectural Central Hospital" #1 sponsor was "Bayer" with 5 trials, followed by "Boehringer Ingelheim" with 5 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored, "Gilead Sciences" with 4 trials sponsored and "Galapagos NV" with 4 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kagawa Prefectural Central Hospital" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator and "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Kagawa Prefectural Central Hospital" are "Ulcerative Colitis" (9 trials), "Crohn's Disease" (4 trials), "Heart Failure" (3 trials), "Alzheimer Disease" (2 trials) and "Atrial Fibrillation" (2 trials). Many other conditions were trialed in "Kagawa Prefectural Central Hospital" in a lesser frequency.

Most popular intervention types in "Kagawa Prefectural Central Hospital" are "Drug" (39 trials), "Other" (4 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Filgotinib" (4 trials), "Empagliflozin" (3 trials), "Etrasimod" (3 trials) and "Mirikizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Kagawa Prefectural Central Hospital" are 39 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Kagawa Prefectural Central Hospital". undefined are not yet recruiting, 7 are recruiting, 12 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 16 completed trials in Kagawa Prefectural Central Hospital, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Kagawa Prefectural Central Hospital, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".